AGM
AKBA icon

Alpine Global Management’s Akebia Therapeutics AKBA Stock Holding History

Alpine Global Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-54,999
Closed -$124K – 443
2021
Q4 		$124K Buy
+54,999
New +$150K 0.02% 605

Other funds holding AKBA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
OCM
Orchard Capital Management Chicago, Illinois $95.9M AUM 45.49% 1-Year Est. Return

Alpine Global Management's AKBA Position: Q1 2022 in Review

Alpine Global Management sold out of Akebia Therapeutics (AKBA) in Q1 2022, closing a stake of 54,999 shares — an estimated $124K sold.

Alpine Global Management first reported a position in AKBA in Q4 2021 and held it in 1 quarter. The position peaked at $124K in Q4 2021. 124 funds tracked by Wall St. Rank hold AKBA as of Q1 2022.

  • Alpine Global Management reported no remaining Akebia Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Alpine Global Management sold 54,999 Akebia Therapeutics shares in Q1 2022, an estimated $124K.
  • Alpine Global Management first reported a position in Akebia Therapeutics in Q4 2021 and held it in 1 quarter.
  • Alpine Global Management's Akebia Therapeutics position peaked at $124K in Q4 2021.
  • 124 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.